Is STTK or NKTX more profitable?

Nkarta's return on equity of -39.64% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% Nkarta N/A -39.64% -30.45%

Does the media prefer STTK or NKTX?

In the previous week, Shattuck Labs had 8 more articles in the media than Nkarta. MarketBeat recorded 10 mentions for Shattuck Labs and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.78 beat Shattuck Labs' score of 1.07 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation and earnings, TECX or NKTX?

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tectonic Therapeutic N/A N/A -$74.15M -$4.57 N/A Nkarta N/A N/A -$104.08M -$1.57 N/A

Is TECX or NKTX more profitable?

Tectonic Therapeutic's return on equity of -35.26% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -35.26% -33.59% Nkarta N/A -39.64% -30.45%

Does the media prefer TECX or NKTX?

In the previous week, Tectonic Therapeutic had 2 more articles in the media than Nkarta. MarketBeat recorded 4 mentions for Tectonic Therapeutic and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.78 beat Tectonic Therapeutic's score of 1.10 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, NKTX or BBOT?

BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.57 N/A BridgeBio Oncology Therapeutics N/A N/A -$134.04M -$2.76 N/A

Is NKTX or BBOT more profitable?

Nkarta's return on equity of -39.64% beat BridgeBio Oncology Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -39.64% -30.45% BridgeBio Oncology Therapeutics N/A -46.90% -42.17%

Which has higher valuation & earnings, MNPR or NKTX?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monopar Therapeutics N/A N/A -$13.72M -$2.17 N/A Nkarta N/A N/A -$104.08M -$1.57 N/A

Is MNPR or NKTX more profitable?

Monopar Therapeutics' return on equity of -13.08% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -13.08% -12.79% Nkarta N/A -39.64% -30.45%

Does the media refer more to MNPR or NKTX?

In the previous week, Monopar Therapeutics had 5 more articles in the media than Nkarta. MarketBeat recorded 7 mentions for Monopar Therapeutics and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.78 beat Monopar Therapeutics' score of 0.56 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is NKTX or ALLO more profitable?

Nkarta's return on equity of -39.64% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -39.64% -30.45% Allogene Therapeutics N/A -50.04% -36.74%

Does the media favor NKTX or ALLO?

In the previous week, Allogene Therapeutics had 11 more articles in the media than Nkarta. MarketBeat recorded 13 mentions for Allogene Therapeutics and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.78 beat Allogene Therapeutics' score of 0.92 indicating that Nkarta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Allogene Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nkarta (NKTX) Competitors

$2.71 -0.05 (-1.81%)

As of 11:28 AM Eastern

Compare

NKTX vs. STTK, TECX, BBOT, MNPR, and ALLO

Should you buy Nkarta stock or one of its competitors? Nkarta's main competitors and comparable companies include Shattuck Labs (STTK), Tectonic Therapeutic (TECX), BridgeBio Oncology Therapeutics (BBOT), Monopar Therapeutics (MNPR), and Allogene Therapeutics (ALLO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nkarta compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Nkarta (NASDAQ:NKTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Shattuck Labs currently has a consensus target price of $12.78, suggesting a potential upside of 85.16%. Nkarta has a consensus target price of $11.20, suggesting a potential upside of 314.05%. Given Nkarta's higher possible upside, analysts plainly believe Nkarta is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Shattuck Labs has higher revenue and earnings than Nkarta. Shattuck Labs is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	692.58	-$48.81M	-$0.51	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A

Nkarta's return on equity of -39.64% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Nkarta	N/A	-39.64%	-30.45%

Shattuck Labs has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

In the previous week, Shattuck Labs had 8 more articles in the media than Nkarta. MarketBeat recorded 10 mentions for Shattuck Labs and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.78 beat Shattuck Labs' score of 1.07 indicating that Nkarta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nkarta	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by insiders. Comparatively, 9.8% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Shattuck Labs beats Nkarta on 8 of the 15 factors compared between the two stocks.

How does Nkarta compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Nkarta (NASDAQ:NKTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Tectonic Therapeutic's return on equity of -35.26% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.26%	-33.59%
Nkarta	N/A	-39.64%	-30.45%

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A

Tectonic Therapeutic has a beta of 3.28, indicating that its stock price is 228% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Tectonic Therapeutic presently has a consensus target price of $77.80, suggesting a potential upside of 150.68%. Nkarta has a consensus target price of $11.20, suggesting a potential upside of 314.05%. Given Nkarta's higher possible upside, analysts plainly believe Nkarta is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 9.8% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Tectonic Therapeutic had 2 more articles in the media than Nkarta. MarketBeat recorded 4 mentions for Tectonic Therapeutic and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.78 beat Tectonic Therapeutic's score of 1.10 indicating that Nkarta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nkarta	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Tectonic Therapeutic and Nkarta tied by winning 7 of the 14 factors compared between the two stocks.

How does Nkarta compare to BridgeBio Oncology Therapeutics?

Nkarta (NASDAQ:NKTX) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

In the previous week, Nkarta had 1 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 2 mentions for Nkarta and 1 mentions for BridgeBio Oncology Therapeutics. Nkarta's average media sentiment score of 1.78 beat BridgeBio Oncology Therapeutics' score of 0.93 indicating that Nkarta is being referred to more favorably in the media.

Company	Overall Sentiment
Nkarta	Very Positive
BridgeBio Oncology Therapeutics	Positive

Nkarta presently has a consensus price target of $11.20, suggesting a potential upside of 314.05%. BridgeBio Oncology Therapeutics has a consensus price target of $24.40, suggesting a potential upside of 185.71%. Given Nkarta's stronger consensus rating and higher possible upside, equities analysts clearly believe Nkarta is more favorable than BridgeBio Oncology Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. 9.8% of Nkarta shares are owned by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nkarta has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Nkarta's return on equity of -39.64% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-39.64%	-30.45%
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%

BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A

Summary

Nkarta beats BridgeBio Oncology Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Nkarta compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Nkarta (NASDAQ:NKTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Monopar Therapeutics had 5 more articles in the media than Nkarta. MarketBeat recorded 7 mentions for Monopar Therapeutics and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.78 beat Monopar Therapeutics' score of 0.56 indicating that Nkarta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nkarta	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A

Monopar Therapeutics presently has a consensus price target of $118.67, suggesting a potential upside of 9.18%. Nkarta has a consensus price target of $11.20, suggesting a potential upside of 314.05%. Given Nkarta's higher possible upside, analysts plainly believe Nkarta is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Monopar Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by company insiders. Comparatively, 9.8% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Monopar Therapeutics' return on equity of -13.08% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
Nkarta	N/A	-39.64%	-30.45%

Summary

Monopar Therapeutics beats Nkarta on 7 of the 13 factors compared between the two stocks.

How does Nkarta compare to Allogene Therapeutics?

Nkarta (NASDAQ:NKTX) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Nkarta's return on equity of -39.64% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-39.64%	-30.45%
Allogene Therapeutics	N/A	-50.04%	-36.74%

Nkarta presently has a consensus price target of $11.20, indicating a potential upside of 314.05%. Allogene Therapeutics has a consensus price target of $8.30, indicating a potential upside of 318.14%. Given Allogene Therapeutics' higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than Nkarta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Nkarta has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market.

Nkarta has higher earnings, but lower revenue than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A
Allogene Therapeutics	$20K	34,289.88	-$190.89M	-$0.67	N/A

In the previous week, Allogene Therapeutics had 11 more articles in the media than Nkarta. MarketBeat recorded 13 mentions for Allogene Therapeutics and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.78 beat Allogene Therapeutics' score of 0.92 indicating that Nkarta is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Allogene Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

80.5% of Nkarta shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 9.8% of Nkarta shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Nkarta and Allogene Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Nkarta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKTX vs. The Competition

Export

Metric	Nkarta	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$193.73M	$3.91B	$7.13B	$12.80B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-1.72	11.65	272.81	25.43
Price / Sales	N/A	1,394.01	686.32	122.60
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	0.61	16.74	11.02	6.33
Net Income	-$104.08M	-$22.71M	$3.47B	$349.46M
7 Day Performance	4.44%	2.47%	1.11%	-0.17%
1 Month Performance	29.43%	12.45%	8.03%	4.26%
1 Year Performance	27.59%	53.62%	23.69%	14.59%

Nkarta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKTX Nkarta	3.3622 of 5 stars	$2.71 -2.0%	$11.20 +314.0%	+30.2%	$193.73M	N/A	N/A	140	Gap Down
STTK Shattuck Labs	3.699 of 5 stars	$7.90 +4.9%	$12.78 +61.7%	+617.8%	$755.73M	$1M	N/A	100	Positive News High Trading Volume
TECX Tectonic Therapeutic	2.9201 of 5 stars	$36.47 -3.1%	$77.80 +113.3%	+39.5%	$735.64M	N/A	N/A	120	Positive News
BBOT BridgeBio Oncology Therapeutics	2.4905 of 5 stars	$9.14 +0.7%	$24.40 +167.0%	N/A	$727.98M	N/A	N/A	N/A
MNPR Monopar Therapeutics	2.32 of 5 stars	$111.36 +3.4%	$118.67 +6.6%	+227.6%	$723.03M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NKTX) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nkarta (NKTX) Competitors

NKTX vs. STTK, TECX, BBOT, MNPR, and ALLO

How does Nkarta compare to Shattuck Labs?

Summary

How does Nkarta compare to Tectonic Therapeutic?

Summary

How does Nkarta compare to BridgeBio Oncology Therapeutics?

Summary

How does Nkarta compare to Monopar Therapeutics?

Summary

How does Nkarta compare to Allogene Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nkarta (NKTX) Competitors

NKTX vs. STTK, TECX, BBOT, MNPR, and ALLO

How does Nkarta compare to Shattuck Labs?

Do analysts recommend STTK or NKTX?

Which has stronger valuation & earnings, STTK or NKTX?

Is STTK or NKTX more profitable?

Which has more risk & volatility, STTK or NKTX?

Does the media prefer STTK or NKTX?

Do insiders & institutionals have more ownership in STTK or NKTX?

Summary

How does Nkarta compare to Tectonic Therapeutic?

Is TECX or NKTX more profitable?

Which has better valuation and earnings, TECX or NKTX?

Which has more volatility & risk, TECX or NKTX?

Do analysts prefer TECX or NKTX?

Do insiders and institutionals have more ownership in TECX or NKTX?

Does the media prefer TECX or NKTX?

Summary

How does Nkarta compare to BridgeBio Oncology Therapeutics?

Does the media favor NKTX or BBOT?

Do analysts recommend NKTX or BBOT?

Do insiders and institutionals have more ownership in NKTX or BBOT?

Which has more volatility and risk, NKTX or BBOT?

Is NKTX or BBOT more profitable?

Which has better valuation & earnings, NKTX or BBOT?

Summary

How does Nkarta compare to Monopar Therapeutics?

Does the media refer more to MNPR or NKTX?

Which has higher valuation & earnings, MNPR or NKTX?

Do analysts prefer MNPR or NKTX?

Which has more risk & volatility, MNPR or NKTX?

Do institutionals and insiders have more ownership in MNPR or NKTX?

Is MNPR or NKTX more profitable?

Summary

How does Nkarta compare to Allogene Therapeutics?

Is NKTX or ALLO more profitable?

Do analysts recommend NKTX or ALLO?

Which has more risk and volatility, NKTX or ALLO?

Which has higher valuation and earnings, NKTX or ALLO?

Does the media favor NKTX or ALLO?

Do institutionals and insiders hold more shares of NKTX or ALLO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools